Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196177583> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W3196177583 endingPage "723" @default.
- W3196177583 startingPage "713" @default.
- W3196177583 abstract "Aim. The article presents the main results of a randomized, double-blind, parallel, placebo controlled trial of DAPA-CKD.
 Materials and methods. The study included patients with chronic kidney disease (CKD) and the possibility of using dapagliflozin at a dose of 10 mg once a day compared with placebo. The study involved 386 centers from 21 countries. A total of 4304 patients were included in the study, the average age was 61.8 years, men predominated, 2906 (67.5%) patients had an initial diagnosis of type 2 diabetes. Patients with diabetic and non-diabetic CKD were included with an estimated glomerular filtration rate (eGFR) of 25 to 75 ml/min/1.73 m2 and a urinary albumin/creatinine ratio of 200 to 5000 mg/g.
 Results. The primary composite endpoint (time to eGFR reduction of 50% or more compared to baseline, time to end-stage renal disease defined as eGFR15 ml/min/1.73 m2, need for chronic dialysis or kidney transplantation, time to renal or cardiovascular death) was shown to occur in 9.2% of patients treated with dapagliflozin and in 14.5% of patients treated with placebo. Also, dapagliflozin therapy was less likely to have a secondary endpoint, such as a combination of a decrease in eGFR by 50% or more, end-stage kidney disease, or renal death. Less frequently, the dapagliflozin group experienced cardiovascular death or hospitalization for heart failure, as well as death from any cause.
 Conclusion. Thus, dapagliflozin demonstrated the ability, in comparison with placebo, to reduce the primary composite point and a number of secondary composite points in patients with both diabetic and non-diabetic CKD." @default.
- W3196177583 created "2021-08-30" @default.
- W3196177583 creator A5021406960 @default.
- W3196177583 date "2021-06-15" @default.
- W3196177583 modified "2023-10-17" @default.
- W3196177583 title "The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study" @default.
- W3196177583 cites W2626446274 @default.
- W3196177583 cites W2756191633 @default.
- W3196177583 cites W2900413769 @default.
- W3196177583 cites W2939222610 @default.
- W3196177583 cites W3005350465 @default.
- W3196177583 cites W3081745704 @default.
- W3196177583 cites W3088173406 @default.
- W3196177583 cites W3101044784 @default.
- W3196177583 cites W3102435759 @default.
- W3196177583 cites W3150973581 @default.
- W3196177583 doi "https://doi.org/10.26442/00403660.2021.6.200891" @default.
- W3196177583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36286839" @default.
- W3196177583 hasPublicationYear "2021" @default.
- W3196177583 type Work @default.
- W3196177583 sameAs 3196177583 @default.
- W3196177583 citedByCount "2" @default.
- W3196177583 countsByYear W31961775832022 @default.
- W3196177583 crossrefType "journal-article" @default.
- W3196177583 hasAuthorship W3196177583A5021406960 @default.
- W3196177583 hasBestOaLocation W31961775831 @default.
- W3196177583 hasConcept C126322002 @default.
- W3196177583 hasConcept C126894567 @default.
- W3196177583 hasConcept C134018914 @default.
- W3196177583 hasConcept C142724271 @default.
- W3196177583 hasConcept C159641895 @default.
- W3196177583 hasConcept C168563851 @default.
- W3196177583 hasConcept C197934379 @default.
- W3196177583 hasConcept C203092338 @default.
- W3196177583 hasConcept C204787440 @default.
- W3196177583 hasConcept C27081682 @default.
- W3196177583 hasConcept C2777180221 @default.
- W3196177583 hasConcept C2777422806 @default.
- W3196177583 hasConcept C2778653478 @default.
- W3196177583 hasConcept C2779978075 @default.
- W3196177583 hasConcept C2780306776 @default.
- W3196177583 hasConcept C555293320 @default.
- W3196177583 hasConcept C71924100 @default.
- W3196177583 hasConceptScore W3196177583C126322002 @default.
- W3196177583 hasConceptScore W3196177583C126894567 @default.
- W3196177583 hasConceptScore W3196177583C134018914 @default.
- W3196177583 hasConceptScore W3196177583C142724271 @default.
- W3196177583 hasConceptScore W3196177583C159641895 @default.
- W3196177583 hasConceptScore W3196177583C168563851 @default.
- W3196177583 hasConceptScore W3196177583C197934379 @default.
- W3196177583 hasConceptScore W3196177583C203092338 @default.
- W3196177583 hasConceptScore W3196177583C204787440 @default.
- W3196177583 hasConceptScore W3196177583C27081682 @default.
- W3196177583 hasConceptScore W3196177583C2777180221 @default.
- W3196177583 hasConceptScore W3196177583C2777422806 @default.
- W3196177583 hasConceptScore W3196177583C2778653478 @default.
- W3196177583 hasConceptScore W3196177583C2779978075 @default.
- W3196177583 hasConceptScore W3196177583C2780306776 @default.
- W3196177583 hasConceptScore W3196177583C555293320 @default.
- W3196177583 hasConceptScore W3196177583C71924100 @default.
- W3196177583 hasIssue "6" @default.
- W3196177583 hasLocation W31961775831 @default.
- W3196177583 hasLocation W31961775832 @default.
- W3196177583 hasOpenAccess W3196177583 @default.
- W3196177583 hasPrimaryLocation W31961775831 @default.
- W3196177583 hasRelatedWork W1984379637 @default.
- W3196177583 hasRelatedWork W2042710484 @default.
- W3196177583 hasRelatedWork W2124543160 @default.
- W3196177583 hasRelatedWork W2329425851 @default.
- W3196177583 hasRelatedWork W2621053019 @default.
- W3196177583 hasRelatedWork W2872957824 @default.
- W3196177583 hasRelatedWork W3111429257 @default.
- W3196177583 hasRelatedWork W3119567526 @default.
- W3196177583 hasRelatedWork W3133946270 @default.
- W3196177583 hasRelatedWork W3201867211 @default.
- W3196177583 hasVolume "93" @default.
- W3196177583 isParatext "false" @default.
- W3196177583 isRetracted "false" @default.
- W3196177583 magId "3196177583" @default.
- W3196177583 workType "article" @default.